TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Aclarion Raises $10.4 Million, Sharpens Focus On Nociscan Rollout

Benzinga Logo Benzinga By Lekha Gupta
Aclarion Raises $10.4 Million, Sharpens Focus On Nociscan Rollout

Aclarion (NASDAQ: ACON) raised $10.4 million through common stock financing at $5.18 per share, extending its cash runway into 2028 with zero debt and $21.6 million in cash. The company plans to accelerate clinical trials for its Nociscan AI platform, expand access across MRI platforms, and pursue broader reimbursement. Despite strong 2025 adoption metrics (69% YoY scan volume growth), the stock fell 5.21% to $4.27, trading at a new 52-week low.

Insights
ACON   neutral

While the company achieved positive operational metrics (69% YoY scan volume growth, 114% Q4 growth) and secured $10.4M in funding with extended runway to 2028, the stock declined 5.21% to a 52-week low on the announcement. This disconnect between positive fundamentals and negative price action suggests market skepticism about valuation or execution risks, warranting a neutral stance.